128 related articles for article (PubMed ID: 8534004)
21. Lenalidomide: a synthetic compound with an evolving role in cancer management.
Saloura V; Grivas PD
Hematology; 2010 Oct; 15(5):318-31. PubMed ID: 20863427
[TBL] [Abstract][Full Text] [Related]
22. [Alpha-interferon in present-day treatment of myeloma].
Demina EA; Votiakova OM
Gematol Transfuziol; 1996; 41(2):32-6. PubMed ID: 8754159
[No Abstract] [Full Text] [Related]
23. Evolving strategies for the treatment of myelomatosis.
Child JA
Br J Haematol; 1994 Dec; 88(4):672-8. PubMed ID: 7819093
[No Abstract] [Full Text] [Related]
24. [The polychemotherapy of patients with multiple myeloma].
Abdulkadyrov KM; Bessmel'tsev SS
Vopr Onkol; 1992; 38(3):345-51. PubMed ID: 1300725
[TBL] [Abstract][Full Text] [Related]
25. Therapy with interferons in blood diseases.
Polli E; Cortelezzi A
Acta Haematol; 1987; 78 Suppl 1():64-9. PubMed ID: 2449025
[TBL] [Abstract][Full Text] [Related]
26. Interferon in the treatment of multiple myeloma and non Hodgkins lymphoma.
Smruti BK; Nair R; Gopal R
J Assoc Physicians India; 1995; Suppl 3():33-7. PubMed ID: 8773120
[No Abstract] [Full Text] [Related]
27. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
28. Interferon in multiple myeloma--does it pay?
Kedar I; Segal A
Isr J Med Sci; 1995 Oct; 31(10):635-7. PubMed ID: 7591691
[No Abstract] [Full Text] [Related]
29. In vitro synergistic activity of PDN-IFN alpha and NM + IFN alpha combinations on fresh bone-marrow samples from multiple myeloma patients.
Lepri E; Barzi A; Menconi E; Portuesi MG; Liberati M
Hematol Oncol; 1991; 9(2):79-86. PubMed ID: 1869244
[TBL] [Abstract][Full Text] [Related]
30. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
[TBL] [Abstract][Full Text] [Related]
31. 2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response.
Millar BC; Bell JB
Br J Cancer; 1995 Dec; 72(6):1525-30. PubMed ID: 8519671
[TBL] [Abstract][Full Text] [Related]
32. Kaposi's sarcoma after autologous bone marrow transplantation for multiple myeloma.
Vivancos P; Sarrá J; Palou J; Valls A; Garćia J; Grañena A
Bone Marrow Transplant; 1996 Apr; 17(4):669-71. PubMed ID: 8722373
[TBL] [Abstract][Full Text] [Related]
33. Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.
Bell JB; Barfoot R; Iveson T; Powles RL; Millar BC
Br J Cancer; 1994 Oct; 70(4):646-51. PubMed ID: 7917911
[TBL] [Abstract][Full Text] [Related]
34. VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma.
Preis P; Scheithauer W; Fritz E; Zielinski C; Kuehrer I; Cortelezzi A; Polli E; Baldini L; Pirker R; Kriegisch A
Onkologie; 1989 Feb; 12(1):27-9. PubMed ID: 2654788
[TBL] [Abstract][Full Text] [Related]
35. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy.
Powles R; Raje N; Horton C; Mehta J; Singhal S; Hickish T; Viner C; Milan S; Treleaven J; Cunningham D
Leuk Lymphoma; 1996 May; 21(5-6):421-7. PubMed ID: 9172806
[TBL] [Abstract][Full Text] [Related]
36. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
37. The role of alpha-interferon in multiple myeloma.
Peest D
Pathol Biol (Paris); 1999 Feb; 47(2):172-7. PubMed ID: 10192884
[TBL] [Abstract][Full Text] [Related]
38. Thalidomide in multiple myeloma.
Rajkumar SV
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):11-6. PubMed ID: 11204667
[TBL] [Abstract][Full Text] [Related]
39. Treatment of cutaneous T cell lymphoma stage II with interferon-alpha-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
Ann N Y Acad Sci; 2001 Sep; 941():210-3. PubMed ID: 11594576
[No Abstract] [Full Text] [Related]
40. Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
Mulder NH; Willemse PH; Schraffordt Koops H; de Vries EG; Sleijfer DT
Br J Cancer; 1990 Dec; 62(6):1006-7. PubMed ID: 2257203
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
